Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Among the many adverse effects induced by immunosuppressive drugs, cancers are a major cause of morbidity and mortality. This review is based on the most recent clinical data. Epidemiological studies and cancer registries have consistently shown an increased risk of malignancies in transplant patients although the calculated risk (4-500-fold increase) differs markedly between studies essentially because of differences in methodologies and selection of patients. Skin and lip cancers, lymphomas and Kaposi's sarcomas are the main types of cancer in these patients. A number of risk factors have been identified, such as latent viral infections, the treatment regimen and the level of immunosuppression. The increasing use of immunosuppressive drugs in nontransplant patients is useful to delineate more accurately the consequences of mild-to-moderate immunosuppression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0300-483x(02)00612-1 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!